Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

An advocacy group that includes the main pharmaceutical lobbying organization, PhRMA, as a member is complaining that a commercial Hims & Hers Health (NYSE:HIMS) is slated to run during the Super Bowl ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...

A RETROSPECTIVE case series has identified ophthalmic complications in patients using the antidiabetic drugs semaglutide and ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance. The approach is especially popular among telemedicine physicians, who ...